Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.
Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment
VITIELLO, BENEDETTO;SCHNEIDER, ROMINA LISBETH;
1998-01-01
Abstract
Cognitive impairment is a common consequence of human immunodeficiency virus (HIV) infection, and dementia is one of the diseases that defines the acquired immunodeficiency syndrome. Peptide T (d-ala-peptide-T-amide) has been reported to block the binding of gp120 to brain tissue and to protect neurons from the toxic effects of gp120 in vitro. In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
heseltine et al.arch neurol.1998.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
203.29 kB
Formato
Adobe PDF
|
203.29 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.